Research programme: chimeric antigen receptor natural killer cell therapeutics - Glycostem/Pieris

Alternative Names: CAR-NK cells based therapeutics - Glycostem/Pieris; CAR-NK cells therapy - Glycostem/Pieris; viveNK^TM-Anticalin therapy

Latest Information Update: 16 Mar 2021

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Glycostem; Pieris Pharmaceuticals
Class Antineoplastics; CAR-NK cell therapies; Gene therapies; Immunotherapies
Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

12 Mar 2021 Glycostem and Pieris Pharmaceuticals agree to co-promote and co-develop CAR-NK therapies in USA and the Netherlands for solid tumours
12 Mar 2021 Early research in Solid tumours in USA, Netherlands (Parenteral) in March 2021
17 Dec 2020 Glycostem in-licenses NK cell production technology from Ghent University

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com